Denali Therapeutics (DNLI) Prices 7.826M Share Common Offering at $23/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Pre-Open Stock Movers 1/28: (DLPH) (XLRN) (ALKS) Higher (EROS) (BWA) (DDD) Lower (more...)
January 28, 2020 9:23 AM ESTToday's Pre-Open Stock Moves
Delphi Technologies PLC (NYSE: DLPH) 61.8% HIGHER; BorgWarner Inc. (NYSE: BWA) and Delphi Technologies PLC (NYSE:... More
After-Hours Movers 01/27: (XLRN) (SURF) (INO) Higher; (EROS) (FFIV) (RMBS) Lower (more...)
January 27, 2020 5:58 PM ESTToday's After-Hours Moves
Acceleron Pharma Inc. (NASDAQ: XLRN) 66.5% HIGHER; announced that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial hypertension (PAH).
Surface Oncology (NASDAQ: SURF) 13.8% HIGHER; announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) applications for its antibody candidates, SRF617 (targeting CD39) and SRF388 (targeting IL-27), and the Company is executing on plans to initiate clinical trials to advance both... More
Denali Therapeutics (DNLI) to Offer $150M in Common Stock
January 27, 2020 4:11 PM ESTDenali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $150 million of shares of its common stock. In addition, Denali Therapeutics intends to grant the underwriters a... More
UPDATE: Goldman Sachs Upgrades Denali Therapeutics Inc. (DNLI) to Buy on EMerging Triple Platform
January 27, 2020 4:30 AM EST(Updated - January 27, 2020 4:46 AM EST)
(updating comment)
Goldman Sachs analyst Salveen Richter upgraded Denali Therapeutics Inc. (NASDAQ: DNLI) from Neutral to Buy with a price target of $37.00 (from $20.00).
The analyst comments "With positive updates from Ph1b DNL201 and Ph1... More
